Synthetic lethal interaction between ARID1A mutation and BET bromodomain inhibition in ovarian clear cell carcinoma

被引：2
|
作者：
Berns, Katrien
Caumanns, Joseph J.
Hijmans, E. Marielle
Gennissen, Annemiek
Evers, Bastiaan
Wisman, Bea A.
Meersema, Gert Jan
Lieftink, Cor
Beijersbergen, Roderick L.
Itamochi, Hiroaki
van der Zee, Ate G.
de Jong, Steven
Bernards, Rene
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-3380
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3380
引用
收藏
页数：2
相关论文
共 50 条
  • [1] ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies
    Caumanns, Joseph J.
    Wisman, G. Bea A.
    Berns, Katrien
    van der Zee, Ate G. J.
    de Jong, Steven
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2018, 1870 (02): : 176 - 184
  • [2] ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
    Katrien Berns
    Joseph J. Caumanns
    E. Marielle Hijmans
    Annemiek M. C. Gennissen
    Tesa M. Severson
    Bastiaan Evers
    G. Bea A. Wisman
    Gert Jan Meersma
    Cor Lieftink
    Roderick L. Beijersbergen
    Hiroaki Itamochi
    Ate G. J. van der Zee
    Steven de Jong
    René Bernards
    Oncogene, 2018, 37 : 4611 - 4625
  • [3] ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
    Berns, Katrien
    Caumanns, Joseph J.
    Hijmans, E. Marielle
    Gennissen, Annemiek M. C.
    Severson, Tesa M.
    Evers, Bastiaan
    Wisman, G. Bea A.
    Meersma, Gert Jan
    Lieftink, Cor
    Beijersbergen, Roderick L.
    Itamochi, Hiroaki
    van der Zee, Ate G. J.
    de Jong, Steven
    Bernards, Rene
    ONCOGENE, 2018, 37 (33) : 4611 - 4625
  • [4] ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer
    Kuroda, Yuka
    Chiyoda, Tatsuyuki
    Kawaida, Miho
    Nakamura, Kohei
    Aimono, Eriko
    Yoshimura, Takuma
    Takahashi, Mio
    Saotome, Keiko
    Yoshihama, Tomoko
    Iwasa, Naomi
    Sakai, Kensuke
    Yamagami, Wataru
    Nishihara, Hiroshi
    Aoki, Daisuke
    GYNECOLOGIC ONCOLOGY, 2021, 162 (03) : 679 - 685
  • [5] ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component
    Nishikimi, Kyoko
    Kiyokawa, Takako
    Tate, Shinichi
    Iwamoto, Masami
    Shozu, Makio
    HISTOPATHOLOGY, 2015, 67 (06) : 866 - 871
  • [6] Clinicopathological Significance of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
    Maeda, D.
    Mao, T-L
    Fukayama, M.
    Wang, T-L
    Shih, I-M
    MODERN PATHOLOGY, 2011, 24 : 259A - 259A
  • [7] Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations
    Bitler, Benjamin G.
    Aird, Katherine M.
    Zhang, Rugang
    MOLECULAR & CELLULAR ONCOLOGY, 2016, 3 (01):
  • [8] Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
    Maeda, Daichi
    Mao, Tsui-Lien
    Fukayama, Masashi
    Nakagawa, Shunsuke
    Yano, Tetsu
    Taketani, Yuji
    Shih, Ie-Ming
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2010, 11 (12): : 5121 - 5129
  • [9] Clinicopathological Significance of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma.
    Maeda, D.
    Mao, T-L
    Fukayama, M.
    Wang, T-L
    Shih, I-M
    LABORATORY INVESTIGATION, 2011, 91 : 259A - 259A
  • [10] The role of chromatin remodeler protein ARID1a in ovarian clear cell carcinoma
    Lakshminarasimhan, Ranjani
    Andreu-Vieyra, Claudia
    Lawrenson, Kate
    Gayther, Simon A.
    Jones, Peter A.
    Liang, Gangning
    CANCER RESEARCH, 2016, 76
12345